David Jones
- Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAINBy Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilAlvar Agusti1Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainPaul W. Jones2St George's, University of London, London, United KingdomEric Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluation Unit, University of South Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Amirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Amirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Amirall, Barcelona, Spain
- Nitrosoglutathione reductase inhibition in the airway epithelium may contribute to lung cancer riskBy Nadzeya Marozkina, David Jones, Sean Yemen and Benjamin GastonNadzeya MarozkinaPediatrics, University of Virginia School of Medicine, Charlottesville, VA, United StatesDavid JonesPediatrics, University of Virginia School of Medicine, Charlottesville, VA, United StatesSean YemenPediatrics, University of Virginia School of Medicine, Charlottesville, VA, United StatesBenjamin GastonPediatrics, University of Virginia School of Medicine, Charlottesville, VA, United States
- COPD disease severity stratification obtained by electronic review of routinely collected primary care dataBy Dermot Ryan, Feargal Ryan, Catherine Blackaby, Rupert Jones and David PriceDermot RyanFeargal Ryan3Clinical Review Services, Optimum Patient Care, Norwich, United KingdomCatherine Blackaby4NHS Improvement: Lung, NHS, Leicester, United KingdomRupert Jones5GP, Armada Surgery, Plymouth, United Kingdom
- Comorbidities at time of COPD diagnosisBy David Price, David Halpin, Robert Winter, Susan Hill, Eric Bateman, Daryl Freeman, Dermot Ryan, Matthew Kearney, Kevin Holton, Annie Burden, Julie von Ziegenweidt, Laurence Mascarenhas, Alison Chisholm and Rupert JonesDavid PriceDavid Halpin3Royal Devon & Exeter Hospital, NHS Foundation Trust, Exeter, United KingdomRobert WinterSusan Hill4Respiratory Programme, Department of Health, London, United KingdomEric Bateman6Respiratory Medicine, University of Cape Town, Cape Town, South AfricaDaryl Freeman7General Practice with Specialist Interest in Respiratory Medicine, Sheringham Medical Practice, Norfolk, United KingdomDermot Ryan8General Practice with Specialist Interest in Respiratory Medicine, Woodbrook Medical Centre, Loughborough, United KingdomMatthew KearneyKevin Holton4Respiratory Programme, Department of Health, London, United KingdomAnnie Burden2Observational Research, Research in Real Life, Norwich, United KingdomJulie von Ziegenweidt2Observational Research, Research in Real Life, Norwich, United KingdomLaurence Mascarenhas2Observational Research, Research in Real Life, Norwich, United KingdomAlison Chisholm2Observational Research, Research in Real Life, Norwich, United KingdomRupert Jones10Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom
- Missed opportunities to diagnose COPDBy David Price, David Halpin, Robert Winter, Susan L. Hill, Eric Bateman, Daryl Freeman, Dermot Ryan, Matthew Kearney, Kevin Holton, Annie Burden, Julie von Ziegenweidt, Laurence Mascarenhas, Alison Chisholm and Rupert JonesDavid PriceDavid Halpin3Royal Devon & Exeter Hospital, NHS Foundation Trust, Exeter, United KingdomRobert WinterSusan L. Hill4Respiratory Programme, Department of Health, London, United KingdomEric Bateman6Respiratory Medicine, University of Cape Town, Cape Town, South AfricaDaryl Freeman7General Practice with Specialist Interest in Respiratory Medicine, Sheringham Medical Practice, Norfolk, United KingdomDermot Ryan8General Practice with Specialist Interest in Respiratory Medicine, Woodbrook Medical Centre, Loughborough, United KingdomMatthew KearneyKevin Holton4Respiratory Programme, Department of Health, London, United KingdomAnnie Burden2Observational Research, Research in Real Life, Norwich, United KingdomJulie von Ziegenweidt2Observational Research, Research in Real Life, Norwich, United KingdomLaurence Mascarenhas2Observational Research, Research in Real Life, Norwich, United KingdomAlison Chisholm2Observational Research, Research in Real Life, Norwich, United KingdomRupert Jones10Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom
- Novel study design to assess the utility of the COPD assessment test (CAT)By Kevin Gruffydd-Jones, Helen Pearce, Steve Holmes, Peter Kardos, Roger Escamila, Roberto Dal Negro, June Roberts, Gilbert Nadeau, David Leather and Paul JonesKevin Gruffydd-Jones1Box Surgery, Box, Corsham, United KingdomHelen Pearce2Respiratory Centre of Excellence, GlaxoSmithKline, London, United KingdomSteve Holmes3Park Road Surgery, Shepton Mallet, Somerset, United KingdomPeter Kardos4Gemeinschaftspraxis und Zentrum für Pneumologie, Allergologie, Schlafmedizin, Klinik Maingau, Frankfurt, GermanyRoger Escamila5Service de Pneumologie, Hôpital Larrey- CHU Toulouse, Toulouse, FranceRoberto Dal Negro6Divisione di Pneumologia, Ospedale Civile Orlandi di Bussolengo, Bussolengo, Verona, ItalyJune Roberts7Clinical Sciences Building, Salford Royal Hospital Foundation Trust, Salford, United KingdomGilbert Nadeau2Respiratory Centre of Excellence, GlaxoSmithKline, London, United KingdomDavid Leather2Respiratory Centre of Excellence, GlaxoSmithKline, London, United KingdomPaul Jones8Clincial Sciences, St George's University of London, London, United Kingdom
- The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary diseaseBy Eric D. Bateman, David Singh, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilEric D. Bateman1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaDavid Singh2Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)By David Singh, Eric D. Bateman, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilDavid Singh1Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomEric D. Bateman2Division of Pulmonology, University of Cape Town, Cape Town, South AfricaPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAINBy Paul W. Jones, Alvar Agusti, Eric D. Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, London, United KingdomAlvar Agusti2Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainEric D. Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluations Unit, University of Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAINBy Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, United KingdomDavid Singh2Medicines Evaluation Unit Ltd, Manchester, United KingdomAlvar Agusti3Thorax Institute, Hospital Clínic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, SpainEric D. Bateman4University of Cape Town, South AfricaRosa Lamarca5Almirall S.A, Barcelona, SpainGonzalo de Miquel5Almirall S.A, Barcelona, SpainCynthia Caracta6Forest Research Institute, NJ, United StatesEsther Garcia Gil5Almirall S.A, Barcelona, Spain
- Electronic screening tool for pneumonia: Performance and utilizationBy Barbara Jones, David Collingridge, Al Jephson, Jeffrey Ferraro, Kumar Mynam, Peter Haug, Herman Post, Caroline Vines, Todd Allen and Nathan DeanBarbara Jones1Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT, United States2Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT, United StatesDavid Collingridge2Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT, United StatesAl Jephson2Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT, United StatesJeffrey Ferraro3Homer Warner Department of Bioinformatics, Intermountain Medical Center, Murray, UT, United StatesKumar Mynam1Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT, United StatesPeter Haug3Homer Warner Department of Bioinformatics, Intermountain Medical Center, Murray, UT, United StatesHerman Post3Homer Warner Department of Bioinformatics, Intermountain Medical Center, Murray, UT, United StatesCaroline Vines4Emergency Medicine, Intermountain Medical Center, Murray, UT, United States5Emergency Medicine, University of Utah, Salt Lake City, UT, United StatesTodd Allen4Emergency Medicine, Intermountain Medical Center, Murray, UT, United StatesNathan Dean1Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT, United States2Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT, United States
- Changes in heart rate and blood pressure variability during and following a period of slow breathingBy Chulee Jones, Sherwin Asadi, Arschang Valipour, David Jones and Otto BurghuberChulee Jones1School of Physical Therapy, University of Khon Kaen, ThailandSherwin Asadi1School of Physical Therapy, University of Khon Kaen, ThailandArschang Valipour1School of Physical Therapy, University of Khon Kaen, ThailandDavid Jones1School of Physical Therapy, University of Khon Kaen, ThailandOtto Burghuber1School of Physical Therapy, University of Khon Kaen, Thailand
- The journey to severe obstructive lung disease - Retrospective study of FEV1 declineBy Rupert Jones, Matthew Masoli, Adam Qureshi, Helen Grover, Gemma Hayes, Fawzi Ali and David JonesRupert Jones1Primary Care, Peninsula College of Medicine and Dentistry, Plymouth, Devon, United KingdomMatthew Masoli2Respiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, Devon, United KingdomAdam Qureshi1Primary Care, Peninsula College of Medicine and Dentistry, Plymouth, Devon, United KingdomHelen Grover2Respiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, Devon, United KingdomGemma Hayes2Respiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, Devon, United KingdomFawzi Ali2Respiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, Devon, United KingdomDavid Jones1Primary Care, Peninsula College of Medicine and Dentistry, Plymouth, Devon, United Kingdom
- Inappropriate prescriptions following initial COPD diagnosisBy Rupert Jones, Nick Freemantle, Marc Miravitlles, Guy Bruselle, Kevin Gruffydd-Jones, Mike Baldwin, Rebecca Stewart, Anna Rigazio, Annie Burden and David PriceRupert Jones1Schools of Medicine and Dentistry, Plymouth University Peninsula, Plymouth, United StatesNick Freemantle2Clinical Epidemiology & Biostatistics, UCL Medical School, London, United KingdomMarc Miravitlles3Department of Pneumology, Hospital Clinic, Barcelona, SpainGuy Bruselle4Clinic of Respiratory Medicine, University Hospital Ghent, Ghent, BelgiumKevin Gruffydd-Jones5GP, Box Surgery, Wiltshire, United KingdomMike Baldwin6Novartis, Novartis Research Centre, Horsham, United KingdomRebecca Stewart7Research in Real Life, RIRL, Cambridge, United KingdomAnna Rigazio7Research in Real Life, RIRL, Cambridge, United KingdomAnnie Burden7Research in Real Life, RIRL, Cambridge, United KingdomDavid Price7Research in Real Life, RIRL, Cambridge, United Kingdom8Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
- Blood eosinophilia and the number of exacerbations in COPD patientsBy David Price, Anna Rigazio, Dirkje Postma, Alberto Papi, Bruselle Guy, Alvar Agusti, Antonio Anzueto, Claus Vogelmeier, Dermot Ryan, Daryl Freeman, Mike Thomas, Ian Pavord, Mona Bafadhel, Nicolas Roche, Rupert Jones, Ted Popov, Emilio Pizzichini, Alison Chisholm and Marjan KerkhofDavid Price1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom2Center of Academic Primary Care, University of Aberdeen, Aberdeen, United KingdomAnna Rigazio3Research in Real Life Ltd, (RiRL), Cambridge, United KingdomDirkje Postma1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom4Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsAlberto Papi1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom5Respiratory Medicine and Research Center on Asthma and COPD, University of Ferrara, Ferrara, ItalyBruselle Guy1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom6Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAlvar Agusti1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom7Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, SpainAntonio Anzueto1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom8Pulmonary/Critical Care, University of Texas Health Science Center, San Antonio,Claus Vogelmeier1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom9Pulmonary Division, Marburg University Hospital, Marburg, GermanyDermot Ryan1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom10General Practice, Woodbrook Medical Centre, Loughborough, United KingdomDaryl Freeman1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom11General Practice, Mundesley Medical Centre, Norfolk, United KingdomMike Thomas1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom12Department of Primary Care Research, University of Southampton, Southampton, United KingdomIan Pavord1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom13Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United KingdomMona Bafadhel1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom13Department of Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United KingdomNicolas Roche1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom14Department of Respiratory and Intensive Care Medicine, Hôtel-Dieu Hospital by University Paris, Paris, FranceRupert Jones1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom15Peninsula School of Medicine and Dentistry, Plymouth University, Plymouth, United KingdomTed Popov1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom16Clinic of Allergy & Asthma, Medical University Sofia, Sofia, BulgariaEmilio Pizzichini1Respiratory Effectiveness Group, (REG), Cambridge, United Kingdom17Department of Pulmonology, University of Santa Catarin, Florianópolis, BrazilAlison Chisholm1Respiratory Effectiveness Group, (REG), Cambridge, United KingdomMarjan Kerkhof3Research in Real Life Ltd, (RiRL), Cambridge, United Kingdom
- One-year change in health status and outcomes in chronic obstructive pulmonary diseaseBy Sarah Wilke, Paul Jones, Hana Müllerova, Nicholas Locantore, Jorgen Vestbo, Ruth Tal-Singer, Frits Franssen, Alvar Agusti, Per Bakke, Peter Calverley, Harvey Coxson, Courtney Crim, Lisa Edwards, David Lomas, William MacNee, Stephan Rennard, Julie Yates, Emiel Wouters and Martijn SpruitSarah Wilke1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsPaul Jones2Division of Clinical Science, St. George’s University of London, London, United KingdomHana Müllerova3Respiratory Epidemiology, GlaxoSmithKline, Uxbridge, United KingdomNicholas Locantore4GlaxoSmithKline, Research Triangle Park, North Carolina,Jorgen Vestbo5Department of Respiratory Medicine, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark6Respiratory Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation, Manchester, United KingdomRuth Tal-Singer7GlaxoSmithKline, GlaxoSmithKline Research and Development, King of Prussia,Frits Franssen1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsAlvar Agusti8Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Barcelona, SpainPer Bakke9Department of Thoracic Medicine, Institute of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, NorwayPeter Calverley10Division of Infection and Immunity Clinical Sciences Centre, University Hospital Aintree, Liverpool, United KingdomHarvey Coxson11Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancover, CanadaCourtney Crim4GlaxoSmithKline, Research Triangle Park, North Carolina,Lisa Edwards4GlaxoSmithKline, Research Triangle Park, North Carolina,David Lomas12University of Cambridge, Cambridge Institute for Medical Research, Department of Medicine, Cambridge, United KingdomWilliam MacNee13MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United KingdomStephan Rennard14Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha,Julie Yates4GlaxoSmithKline, Research Triangle Park, North Carolina,Emiel Wouters1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands15Department of Respiratory Medicine, Maastricht University Medical Centre+, Maastricht, NetherlandsMartijn Spruit1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands
- The GOLD COPD categories are inaccurate in predicting future risk in a UK primary care dataset and the 2014 changes to cut-off values have not helpedBy Rupert Jones, David Price, Amanda Lee and Niels ChavannesRupert Jones1Peninsula School of Medicine and Dentistry, Plymouth University, Plymouth, Devon, United KingdomDavid Price2Dept of General Practice and Primary Care, University of Aberdeen, Aberdeen, United KingdomAmanda Lee4Medical Statistics, University of Aberdeen, Aberdeen, United KingdomNiels Chavannes3Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands
- The sensitivity and specificity of pseudomonas aeruginosa detection using hydrogen cyanide concentration in exhaled breath – The SPACE studyBy Francis Gilchrist, Andrew Jones, Kevin Webb, David Smith and Warren LenneyFrancis Gilchrist1Academic Depertment of Child Health, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom2Institute of Science and Technolgy in Medicine, Keele University, Keele, United KingdomAndrew Jones3Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Manchester, United KingdomKevin Webb3Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Manchester, United KingdomDavid Smith2Institute of Science and Technolgy in Medicine, Keele University, Keele, United KingdomWarren Lenney1Academic Depertment of Child Health, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom2Institute of Science and Technolgy in Medicine, Keele University, Keele, United Kingdom
- Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient datasetBy David Price, Rupert Jones, Kevin Gruffydd-Jones, Guy Brusselle, Marc Miravitlles, Michael Baldwin, Rebecca Stewart and Dorothy L. KeiningerDavid Price1Centre for Academic Primary Care, University of Aberdeen, Aberbeen, United Kingdom7Clinical Research, Research in Real Life (RIRL) Limited, Cambridge, United KingdomRupert Jones2Clinical Research Fellow, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United KingdomKevin Gruffydd-Jones3GP, Box Surgery, Wiltshire, United KingdomGuy Brusselle4Head of Clinic of Respiratory Medicine at University Hospital Ghent, Ghent University, Ghent, BelgiumMarc Miravitlles5Chest Physician, Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, SpainMichael Baldwin6HE&OR Primary Care, Novartis Pharmaceuticals Limited, Horsham, West Sussex, United KingdomRebecca Stewart7Clinical Research, Research in Real Life (RIRL) Limited, Cambridge, United KingdomDorothy L. Keininger8HE&OR Primary Care, Novartis Pharma AG, Basel, Switzerland
- Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysisBy David Price, Rupert Jones, Kevin Gruffydd-Jones, Guy Brusselle, Marc Miravitlles, Michael Baldwin, Rebecca Stewart and Dorothy L. KeiningerDavid Price1Centre for Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom7Clinical Research, Research in Real Life Limited (RIRL), Cambridge, United KingdomRupert Jones2Clinical Research Fellow, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United KingdomKevin Gruffydd-Jones3GP, Box Surgery, Wiltshire, United KingdomGuy Brusselle4Head, Clinic of Respiratory Medicine, University Hospital Ghent, Ghent University, Ghent, BelgiumMarc Miravitlles5Chest Physician. Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, SpainMichael Baldwin6HE&OR Primary Care, Novartis Pharmaceuticals Limited, Horsham, West Sussex, United KingdomRebecca Stewart7Clinical Research, Research in Real Life Limited (RIRL), Cambridge, United KingdomDorothy L. Keininger8HE&OR Primary Care, Novartis Pharma AG, Basel, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.